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Abstract 
Introduction 
Cell salvaging is a fundamental component of blood conservation during cardiac 
surgery.  It entails intra-operative scavenging, washing and collection of a patient’s 
blood for retransfusion at completion of surgery. During surgery vast amounts of 
heparin is administered to avoid fatal thrombosis in both the bypass and 
autotransfusion circuits. Adequate heparin removal during the cell salvaging process 
is thus crucial to avoid retransfusion of heparin to these high risk patients.  We 
wanted to measure heparin levels in the collected reinfusate prior to retransfusion, in 
order to quantify heparin removal in our current autotransfusion system, the Sorin 
Xtra®. 
Method 
This study was subjected to ethical committee approval prior to initiation 
(S14/03/050). 31 adult patients undergoing on pump cardiac surgery in Tygerberg 
Academic Hospital were recruited after taking informed consent. A standard cell 
salvaging process was used for setup using the Sorin Xtra® autotransfusion system. 
After completion of the cell salvaging process, a blood sample was aspirated from the 
collected reinfusate and stored in a standard citrated blood sampling tube. Sample 
processing and heparin measurement were performed in the haematology laboratory 
of Tygerberg Hospital. A modified anti-Xa heparin assay was employed to measure 
reinfusate heparin levels, since the absence of coagulation factors necessitates the 
addition of a set amount of normal pooled plasma prior to performing the assay.  
Results 
The mean heparin levels measured in the Sorin Xtra® reinfusate were 0.52 (IQR 0.16 
– 0.74; 95% CI 0.30 – 0.66) IU/ml. The 95% confidence intervals did not encroach on
the alternative hypothesis, but did span the value representing the null hypothesis. The 
data thus failed to reject the null hypothesis, indicating clinically significant reinfusate 
heparin levels. Sixteen of 31 reinfusates (56%; 95% confidence interval 35 to 68%) 
exhibited heparin concentrations exceeding 0.5 IU/ml.  There was no clinically 
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significant relationship (r2 0.02, p = 0.46) between heparin dosage administered to the 
patient and the concentration measured in the reinfusate. 
Conclusion 
Clinically significant heparin levels in cell saving reinfusate can potentially worsen 
postoperative bleeding in cardiac surgery. The mean heparin level measured in our 
study was more than the AABB’s recommended value of 0.5IU/ml, and 16 samples 
had absolute values more than this. Although the absolute heparin dose retransfused 
remain debatably low, the possibility of heparin induced coagulopathy should be 
entertained in cardiac patients that received reinfusate from the Sorin Xtra® ATS with 
ongoing postoperative bleeding in our institution.  A practical suggestion in these 
cases would be to quantify heparin activity either with a point of care device 
(TEG/ROTEM) or direct measurement of heparin concentration using an Anti-Xa 
assay and titrating heparin reversal accordingly. 
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Opsomming 
Inleiding 
Eritrosiet-suiweringstoestelle speel ‘n belangrike rol in bloed besparing tydens 
opehart chirurgie.  Dit behels die versameling, was en prosessering van ‘n pasïent se 
eie bloed gedurende chirurgie, met die doel om die geprosesseerde bloed op ‘n latere 
stadium terug te transfuseer. Tydens opehart chirurgie word heparien gebruik om 
stolling in die omleiding- en bloedbesparingsisteme te voorkom, aangesien 
blootstelling aan die negatiewe oppervlakte van díe sisteme wydverspreide 
bloedstolling aktiveer. Heparien verwydering gedurende bloedsuiwering is dus 
noodsaaklik om die hertransfusie daarvan te beperk, omdat betekenisvolle 
heparienvlakke ‘n koagulopatie kan teweegbring in die onmiddelike postoperatiewe 
periode wanneer stolling van uiterste belang is. Heparien suiwering in die betrokke 
toestelle wat in ons instansie gebruik word is nog nie voldoende nagevors nie.  Met 
hierdie studie het ons dus gepoog om die heparien vlakke in geprosesseerde bloed van 
ons huidige selsuiweringstoestel, die Sorin Xtra®, te bepaal. 
Metode 
Die studie is uitgevoer in Tygerberg Akademiese Hospitaal na goedkeuring van die 
etiese komitee(S14/03/050). 31 volwasse pasïente wat opehart chirurgie ondergaan 
het is gewerf na ingeligte toestemming verkry is. Slegs gevalle wat kardiopulmonale 
omleiding benodig het en waarvoor die Sorin Xtra® toestel gebruik is, is genader. Die 
bloedsuiwerings opstelling was gestandardiseer. ‘n Bloedmonster is geneem vanuit 
die geprosesseerde bloed na voltooiing van die suiweringsproses en in ‘n standard 
sitraatbuis geplaas. Die monsters is geneem na Tygerberg Hospitaal se hematologie 
en stollingslaboratorium vir prosessering en meting van heparienvlakke. Om die 
monsters se heparien vlakke akkuraat te meet is ‘n gemodifiseerde anti-Xa toets 
gebruik. Die afwesigheid van stolfaktore en ATIII in die geprosesseerde 
bloedmonsters vereis die toevoeging van normale gepoelde plasma voor die toets 
uitgevoer kan word. 
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Resultaat 
Gemiddelde heparien vlakke van 0.52 (IQR 0.16 – 0.74; 95% CI 0.30 – 0.66) IU/ml is 
gemeet in die geprosesseerde bloed van die Sorin Xtra® toestel. Die 95% 
sekerheidsinterval het nie die alternatiewe hipotese se waarde ingesluit nie, maar wel 
die nul hipotese. Die data het nie die nul hipotese verwerp nie, wat aandui dat die 
gemiddelde heparien vlakke wat gemeet is wel statisties noemenswaardig is. 16 van 
die 31 monsters (56%; 95% sekerheidsinterval 35 to 68%) het heparien vlakke gehad 
van meer as 0.5IU/ml. Daar is geen kliniese verwantskap (r2 0.02, p = 0.46) tussen die 
gemete heparien vlakke en die hoeveelheid heparien wat toegedien is nie. 
Samevatting 
Noemenswaardige heparienvlakke in geprosesseerde bloed van selbesparingstoestelle 
kan post operatiewe bloeding vererger na opehart chirurgie. Die gemiddelde heparien 
vlak in geprosesseerde bloed van die Sorin Xtra® selbesparingstoestel is meer as die 
AABB se voorgestelde waarde van 0.5IU/ml.  Sestien van die 31 monsters het hoër 
vlakke gehad as die voorgestelde waarde van 0.5IU/ml. Alhoewel die absolute dosis 
heparien wat teruggegee word debateerbaar min is, moet heparien geinduseerde 
koagulopatie steeds uitgeskakel word as ‘n moontlike oorsaak van bloeding in hierdie 
groep pasïente wat geprosesseerde bloed van die Sorin Xtra® toestel ontvang het. 
Heparien aktiwiteit kan gekwantifiseer word met behulp van tromboelastografie 
(TEG/ROTEM) of direkte heparien vlak bepaling deur middel van ‘n anti-Xa toets 
om sodoende heparien omkering te lei. 
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Glossary of acronyms and definitions 
 
Acronyms 
 
2,3 DPG: 2,3 Diphosphoglycerate 
ACT:  Activated clotting time 
ATP:  Adenosine triphosphate 
ATIII:  Antithrombin III 
ATS:  Autotransfusion system 
CABG: Coronary artery bypass grafting 
CEO:  Chief executive officer 
CI:  Confidence interval 
CPB:  Cardiopulmonary bypass 
FXa:  activated Factor X 
IQR:   Interquartile range 
IU:  International units 
IU/ml:  International units per millilitre 
MRC:  Medical Research Council 
NHLS:  National Health Laboratory Services 
NPP:  Normal pooled plasma 
ROTEM: Rotating thromboelastometry 
TEG:  Thromboelastography 
 
Definitions 
 
An autotransfusion system (ATS) is also known as a cell saving device or cell salvage 
device.  It entails the device and circuit used during the cell salvaging process. 
 
The terms “cell saving” and “cell salvaging” are synonymous. They define the 
process where a patient’s own blood is scavenged, washed, collected and retransfused 
to the same patient at a later stage, usually throughout the perioperative process. 
 
The terms “salvaged blood”, “cell saved blood” and “reinfusate” implies the 
completed processed product from an autotransfusion device.  These terms are used 
interchangeably in this protocol. 
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“Heparin concentration” and “heparin activity” are used interchangeably in this 
protocol, the latter being the term that better describes heparin measurement 
techniques. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 !!!!!
Stellenbosch University  https://scholar.sun.ac.za
! 12!
1.  Introduction  
 
 
1.1!Cell salvaging in cardiac surgery 
Cell salvaging is the intraoperative process where a patient’s own blood is aspirated 
from the surgical site, after which it is filtered, washed and suspended in normal 
saline for retransfusion at a later stage.  An autotransfusion system (ATS) executes 
this process. Cardiac surgery is associated with massive blood loss, necessitating a 
blood conservation strategy.  Autotransfusion systems are thus routinely employed in 
these surgeries, with the aim of minimising homologous blood transfusion. After 
discontinuation of cardiopulmonary bypass, the ATS processes residual blood from 
the bypass circuit with aspirated blood from the surgical field, after which it is 
retransfused to the patient. At this stage of the operation, normal coagulation is 
paramount to ensure proper haemostasis. This process is complicated by the fact that 
large doses of heparin are necessary to avoid fatal thrombosis during on-pump 
surgeries. The exposure of blood to the negative surface area of the bypass and cell 
salvage circuits results in widespread activation of the clotting cascade via the 
intrinsic pathway.  Adequate heparin removal by the autotransfusion system is thus 
critical, since significant residual heparin levels in salvaged blood can contribute to 
inadequate haemostasis and increased postoperative bleeding. 
 
The rationale behind the use of salvaged blood in cardiac procedures is twofold; 
limiting homologous blood transfusion and improved oxygen carrying capacity of 
reinfusate.  Apart from the well known risks related to transfusion of homologous 
blood and blood products(2, 3) the majority of studies(4-8), barring one(9), has 
indicated that outcome after cardiac surgery is worse after homologous transfusion.  It 
is therefore advisable to limit the exposure of patients to blood and blood products.  
Red cell salvaging is a fundamental component of blood conservation.(2) A 2010 
Cochrane Collaboration systematic review analysed and compared results of 75 trials. 
The systematic review concluded that the use of cell salvaging “reduced the rate of 
exposure to allogeneic red blood cell transfusion by a relative 38%”.(10)  
Salvaged blood has an improved oxygen carrying capacity when compared to 
homologous blood.  The pH, potassium, adenosine triphosphate (ATP) and 2,3-
dishosphoglycerate (2,3-DPG) levels are closer to physiological values than that of 
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homologous blood, optimising the position of the oxygen-hemoglobin dissociation 
curve.(2, 11, 12) The erythrocyte population of salvaged blood maintains their 
biconcave shape and constitutes the young supple cells that survived centrifugation. 
This improves the surface area available for oxygen dissociation across the 
erythrocyte membrane. 
 
 
1.3 Coagulopathy, bleeding and cell salvage 
Although cell salvaging during cardiac surgery has shown to decrease homologous 
transfusion, its effect on postoperative bleeding during cardiac surgery is less clear. 
Some studies show a reduction or no difference in postoperative blood loss (13-16), 
which is contradicted by others that show an increase in blood loss and blood product 
administration associated with cell salvage blood transfusion.(17) Some authors even 
reported an association between the volume of reinfusate administered and 
bleeding.(18, 19)  
 
There are interesting interactions between hemodilution, coagulopathy and cell 
salvage, with some evidence that the product of cell salvage may induce a 
coagulopathy.(2, 18, 20, 21) The reasons why the administration of salvaged blood 
may induce a coagulopathy include: 
1.! The autotransfused “blood” is devoid of coagulation factors, fibrinogen and 
platelets (essentially erythrocytes suspended in a balanced salt solution). Rapid 
administration thereof can aggravate the existing cardiopulmonary bypass induced 
coagulation factor dilution.(18) 
2.! Platelet activation during the cell salvage process can cause transient 
thrombocytopaenia after reinfusion.(20) 
3.! Activation of coagulation by red cell fragments or by mediators released by 
platelets and leukocytes is a probable cause of coagulopathy.  Autologous 
erythrocyte stroma can act as thromboplastin, initiating disseminated 
coagulopathy in animal models.  This remains a theoretical risk as is yet to be 
investigated in a clinical setting.(22) 
4.! Significant amounts of heparin in the reinfusate could aggravate an existing 
coagulopathy.  
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5.! Both heparin rebound(21, 23-25) and also rapid protamine clearance can possibly 
aggravate a (heparin-induced) coagulopathy.(24-32) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 !
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2.! Literature review  
 
2.1 Other devices studied 
A number of studies have investigated whether the end products of ATS contain 
clinically significant amounts of heparin. These mostly suggest that clinically 
insignificant amounts of heparin remain in the end product of the Dideco Electa®, 
Sorin Xtra® and other autotransfusion systems(1, 33-46). These results are 
summarized in Table 1. These studies are subject to criticism and clinically related 
concerns: 
 
1.! Poorly defined heparin removal:  
Heparin elimination is described qualitatively with terms like ‘adequate removal’, 
‘virtual elimination’ and ‘contains insignificant amounts’ in many of the studies. This 
makes them of uncertain clinical relevance since absolute heparin concentrations are 
not described.  Others report heparin elimination as a percentage and not as absolute 
amounts.  While elimination rates of ‘98.8-99.9%’ and ‘98.7 ± 0.2%’ appear 
impressive, these are of unknown clinical significance. 
 
2.! They are irrelevant to our institution:  
The devices studied that reported absolute heparin concentrations are different from 
the cell saving devices employed at our institution.  These studies include the ones 
conducted by Ottesen, Paravicini, Sandmann, McShane, Kling, Sistino, Gravlee, 
Rougé, Kalra, Vorweg, Geiger as stated in Table 1.  
 
3.! The accuracy of their heparin measurement is debatable: 
The measurement of heparin in plasma relies on the presence of ATIII.  Reinfusate, 
being completely devoid of any coagulation factors, has to undergo reconstitution 
with plasma prior to the measurement of the anti-Xa assay (see “Methodology”).  The 
majority of published studies either did not specify their assay, and when they did 
specify, they did not mention whether they reconstituted their samples with NPP prior 
to performing the assay. This makes the accuracy doubtful. The various assays 
employed for each study is specified in Table 1. 
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In summary, the available research above suggests that no significant amounts of 
heparin remain in salvaged reinfusate, although their measurement technique 
employed is doubtful.  Details of the cell saving devices employed at our institution 
are unknown. 
 
2.2 Devices used at Tygerberg Hospital 
The former cell saving device employed at our cardiac suites was the Dideco Electa® 
autotransfusion system.  An initial, similar study was performed on this device in 
2010 by Dr WF Buys and Prof AI Levin to determine reinfusate heparin levels(1).  
This study concluded that reinfusate from the Dideco Electa® device contained a 
mean heparin value of 0.2IU/ml(±0.17IU/ml), which was statistically insignificant. In 
the meantime a newer ATS, Sorin Xtra®, was employed at Tygerberg Hospital, 
claiming an improved heparin elimination rate. The bowl sizes used at Tygerberg 
Hospital are 225ml (heparin elimination of 98.8% with a standard deviation of ± 1%) 
and 175ml (heparin elimination of 99.9% with a standard deviation of ± 0.5%).  The 
standard wash cycle is delineated as POPT, the default settings of the Sorin Xtra® 
ATS.(47) Absolute reinfusate heparin levels for these specific cycles are yet to be 
published.  
 
2.4 Study objective and statistical planning 
The primary objective of this study was to determine absolute heparin levels in the 
Sorin Xtra® ATS reinfusate in a single centred, prospective, non-randomized, 
observational study.  The secondary objective of this study was to compare heparin 
concentrations in the Dideco Electa® and Sorin Xtra® reinfusates, incorporating the 
data obtained from the previous study performed by Buys and Levin et al.  The results 
from both studies were reported in a research article, which has subsequently been  
published in the Journal of Cardiothoracic and Vascular Anesthesia.(1) 
Mr Justin Harvey from the Centre for Statistical Consultation at the Tygerberg 
Campus, as well as professors JF Coetzee and AI Levin from the Department of 
Anaesthesiology and Critical Care were consulted on the design and statistical 
analysis of this study.  
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Null hypothesis: Cell salvaged blood produced by the Sorin Xtra® autotransfusion 
system contains clinically significant concentrations of heparin. 
Alternative hypothesis: Cell salvaged blood produced by the Sorin Xtra® 
autotransfusion system contains clinically insignificant concentrations of heparin. 
 
To determine how many patients would need to be studied, we interrogated published 
studies describing residual heparin levels in cell saver blood. The American 
Association of Blood Bank’s 5th edition (2013) of “Standards for preoperative 
autologous blood collection and administration” agreed that heparin levels of less than 
0.5 anti Xa IU/ml were insignificant.(48) Buys and Levin found heparin levels of 0.2 
± 0.17IU/ml in salvaged blood from the Dideco Electa® autotransfusion system(1).  
We thus based our analysis on finding a difference (effect size) of 0.5 IU between the 
null hypothesis and the alternative hypothesis.  PASS (Hintze, J.  (2008).  PASS 2009. 
NCSS, LCC.  Kaysville, Utah.  www.ncss.com) was used to estimate the sample size.  
A sample size of 29 achieves 81.4% power to detect a difference of -0.5 between the 
null hypothesis correlation of 0.0 and the alternative hypothesis correlation of 0.5 
using a two sided hypothesis test with a significance level of 0.05.  This is the similar 
power analysis used to determine the sample size in Buys and Levin’s previous study. 
In order to compare this study’s results with that of the previously performed study, 
the study design, methodology and measurement techniques were kept similar.  The 
study was performed in the same theatre complex, with a similar case mix.  Heparin 
levels measured in the cell saver blood from the Sorin Xtra® ATS were subsequntly 
entered into an Excel spread sheet (Appendix A) and statistically analysed. 
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3.  Methodology 
3.1!  Patient recruitment 
The following inclusion criteria qualified patients to be eligible for recruitment: 
I.! Patients undergoing elective or emergency cardiac surgery at Tygerberg 
Academic Hospital where the Sorin Xtra® autotransfusion system is used for 
intraoperative blood salvage.  
II.! Patients scheduled for both coronary artery bypass graft (CABG) and/or valve 
replacement procedures.  
III.! Patients that are scheduled to have on-pump surgery.  
IV.! Adult patients more than 18 years of age that weigh more than 45 kilograms. 
V.! Patients that have agreed to participate and have given informed consent. 
 
Exclusion criteria include 
I.! Paediatric cases and patients younger than 18 years of age. 
II.! Patients that do not give consent. 
III.! Non-cardiac surgery where the cell saver is going to be used. 
IV.! Patients that are scheduled to have off-pump surgery will be excluded from 
this study.  
 
3.2! Cell salvaging process 
The standard cell salvaging process employed is delineated below:  
1.! During the procedure, shed blood is aspirated, filtered and collected into the cell 
saver reservoir. After discontinuation of CPB, any remaining blood from the 
heart-lung machine is also processed by the ATS. 
2.! The aspirated fluid undergoes continuous centrifugation to separate erythrocytes 
from other components such as plasma, saline, platelets, proteins, free 
haemoglobin, amniotic fluid, fat droplets and malignant cells. 
3.! Once a sufficient volume has been collected, the red blood cells are washed.  
Salvaging setup was standardised with regards to bowl size and washing cycle.  
One bowl size (225ml) and wash program (POPT) were used for all cases. 
4.! A separate bag of normal saline without anticoagulant is used for ‘washing’ 
purposes.  The reinfusate consists of salvaged erythrocytes suspended in normal 
saline with a haematocrit approaching 58-63%, depending on the bowl size and 
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wash cycle employed (bowl sizes 225 ml and 175ml are associated with a 
haematocrit of 63% and 58% respectively when the default washing program, 
POPT is used).(47) 
5.! The reinfusate must be transfused to the patient within 6 to 8 hours after 
completion of the washing process.(2) 
!
3.3!  Heparin sources 
Prior to institution of cardiopulmonary bypass, the anaesthetist administers a dose of 
200-300 IU/kg body weight intravenously, aiming for an ACT of more than 400 
seconds.  Additional heparin is administered if this target is not reached. The 
perfusionist adds heparin to the priming solution of the circuit during the initial setup.  
Additional heparin will be added during bypass time to maintain an ACT of more 
than 400 seconds. During cell salvaging, a solution of one litre of normal saline, to 
which 25 000 IU of unfractionated heparin has been added, is continuously aspirated 
into the cell saver reservoir to prevent clotting of the scavenged blood. Heparin levels 
up to 22.9 U/ml (median of 6.3 U/ml)(11) has been measured in the reservoir. This 
emphasises the importance of adequate heparin elimination by the ATS. 
 
3.4! Sampling management and processing 
 
After completion of the cell salvaging process, reinfusate is collected in a bag 
supplied by the manufacturer. A 4.5 millilitre sample was taken directly from the bag 
of reinfusate before initiation of transfusion. This sample was taken in a standard 
sodium citrate sampling tube and dispatched to the haematology laboratory, where it 
was centrifuged at 4000 revolutions per minute for 20 minutes. Sample storage at -80 
degrees Celsius after centrifugation, ensures heparin stability for a considerable time. 
The tubes were de-identified and a consecutive numbering system employed to 
protect personal information of each patient. Each sample number was used to label 
all specimens and data capture sheets. Please see appendix E for an example of the 
data capture sheets that were used. 
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3.5! Heparin measurement 
Heparin levels were measured using an anti-Xa chromogenic assay. This test is based 
on a synthetic chromogenic substrate and on Factor Xa inactivation. It is used for the 
quantitative determination of unfractionated heparin and low molecular weight 
heparin activity in human citrated plasma. Washing of blood with a ATS removes 
most of the plasma proteins including clotting factors and AT III. At the start of this 
test, cell saver blood is supplemented with purified AT III. The heparin in the sample 
forms complexes with the AT III. A known amount of FXa is then added, which 
results in the formation of heparin-ATIII-FXa complexes. The excess FXa, which 
remains, releases the chromogen p-nitroanaline from a chromogenic substrate. The 
amount of p-nitroanaline is inversely proportional to the amount of heparin in the 
sample.(49) 
Quality control: Controls were run before any number of batched tests were 
conducted. For calibration purposes a standard preparation of 0.8 units of heparin per 
millilitre was prepared using the same heparin used during CPB. Normal Pooled 
Plasma (NPP) was used in preparation of the standard. During the control sample 
testing, we consistently found results with almost half the value of the known 
concentrations prepared for control purposes. Similar problems have been 
encountered in studies employing heparin chromogenic tests in samples not 
resembling plasma. The study of heparan sulphate’s anticoagulant activity in human 
follicular fluid by de Agostini et al(50) is one example. In this study the problem was 
solved by measuring the anti-Factor Xa level after making 1:2 to 1:16 dilutions in 
normal plasma and correcting for this dilution with the appropriate calculations. We 
have found that making 1:2 dilutions of our samples with normal pooled plasma 
resulted in control samples with reliable results. 
 
3.6 Data storage  
Results from the heparin analysis was accumulated and presented in Excel document 
format (Appendix A).  
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3.7!Ethical aspects 
The study was approved by the Committee for Human Research of the University of 
Stellenbosch on the 08-08-2014 (Reference: S14/03/050, see appendix B). The 
research conducted adhered to the ethical guidelines and principles of the 
International Declaration of Helsinki, South African Guidelines for Good Clinical 
Practice and the Medical Research Council (MRC) Ethical Guidelines for Research. 
The aim of this study was to provide answers in improving the quality of care of 
patients receiving cell saver blood in our institution.  There was no perverse incentive, 
and no investigator had any relationship, commercial or otherwise, with the company 
or its employees that supply the device. The study population was fairly chosen, and 
not particularly vulnerable. No groups that could benefit from the research were 
excluded. Patient autonomy was respected through invitation to join the study with a 
personal interview by the lead investigator preoperatively. Informed consent was 
taken during this interview and included an explanation of the study, its implications 
and possible benefits.  Each patient was provided an information sheet that included 
the contact numbers of the ethical committee and investigator, should they have any 
queries (Appendix C,D). Patient identity was protected by de-identification of the 
samples using a numbering system during collection.  The data sheets with the 
patient’s identities were collected by the lead investigator and kept securely.  
 
3.8 Resources 
The Sorin Xtra® Cell Separator device is currently in use at Tygerberg Academic 
Hospital as standard practice for all cardiac related procedures requiring CPB.  
Written permission was obtained from the CEO (Dr Erasmus) of Tygerberg Hospital 
to perform the study. The modified Anti-Xa assay was performed by the same 
laboratory technologist involved in the first study (Ms Marieta du Plessis). The tests 
were performed by the National Health Laboratory Services (NHLS) on site at 
Tygerberg Hospital.  Written permission was obtained from the NHLS to utilise the 
laboratory services and staff in support of this study.  The account from the NHLS 
was settled by the Department of Anesthesiology, from their research fund.  A 
R15000 research bursary from the Harry Croxley fund was utilised for this. 
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4.!Results and discussion 
31 patients were enrolled in this study. Mean reinfusate heparin levels measured from 
the Sorin® Xtra® ATS were 0.52 (interquartile range 0.16 to 0.74; 95% confidence 
interval 0.30 to 0.66) IU/ml(see Figure 1). The null hypothesis tested by a one-sample 
test against 0.5 U/mL was that the Sorin Xtra® reinfusate contained clinically 
significant heparin concentrations. The data failed to reject the null hypothesis and 
thus are consistent with clinically significant reinfusate heparin concentrations. 
Sixteen of 31 reinfusates (56%; 95% confidence interval 35 to 68%) exhibited heparin 
concentrations exceeding 0.5 IU/ml. There was no significant relationship between 
the heparin dosages administered to the patient and reinfusate heparin 
concentrations(r2 0.02, p = 0.46).   
The 2002 and subsequent American Association of Blood Banks’ guidelines state that 
reinfusate heparin concentrations should be below 0.5 anti-Xa IU/ml.(46, 48, 51, 52) 
This is identical to Yawn and colleagues’ recommendation, but slightly higher than 
Umlas and colleague’s suggested maximal range of 0.2 to 0.4 IU/ml.(33, 34) The 
average reinfused heparin doses would be 418 IU (6.0 IU/kg for a 70 kg patient) 
representing very small doses of heparin compared to those typically administered 
(200 to 300 IU/kg) before initiation of cardiopulmonary bypass.  Such small doses of 
heparin are likely inconsequential. We elected not to investigate either the effects of 
these small dosages of heparin or the deleterious effects of the reinfusate on the 
vulnerable coagulation status or bleeding following cardiac surgery. Not doing so 
does represent a limitation of our study. However, accounting for all possible above-
mentioned reinfusate anticoagulant effects would be costly and complicated, point of 
care identification of low levels of residual heparin being difficult.(23, 53-57) 
 
Our primary concern was whether the autotransfusion systems tested efficiently 
removed heparin, since reinfusate containing significant amounts of heparin could 
aggravate post cardiopulmonary bypass coagulopathy. Previous studies investigating 
cell saver reinfusates, have measured similar or even higher (0.64, 0.67 to 1.71, and 
0.61 to 0.8 IU/ml) heparin concentrations than in our studies (Table 1).(40-43) To 
ensure reinfusate heparin concentrations were measured accurately, it is essential to 
report the measurement method used and to explicitly state that the critical 
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modification described above was employed. It is unclear whether this critical 
modification was indeed employed in any of the previous studies investigating 
reinfusate heparin concentrations (Table 1), nonconformity causing underestimation 
of reinfusate heparin concentrations.(11, 33, 35-47, 58-60) 
The volume of heparin containing wash fluid did not affect reinfusate heparin 
concentrations. In one of the few studies examining device performance, differing cell 
saver wash regimens did not affect heparin elimination.(47) In this respect, a further 
limitation of our study was not studying the effect of different washing regimens 
(alterations of the number of wash cycles, volumes of saline used to wash the 
reinfusate, wash fluid heparin concentrations or bowl sizes) and reinfusate heparin 
concentrations. As some aging devices have performed poorly, periodic quality 
control of reinfusate composition, including heparin concentrations, has been 
recommended.  
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5.!Conclusion 
Clinically significant heparin levels in cell saving reinfusate can potentially worsen 
postoperative bleeding in cardiac surgery. The mean heparin level measured in our 
study was more than the AABB’s recommended value of 0.5IU/ml, and 16 samples 
had absolute values more than this. Although the absolute heparin dose retransfused 
remain debatably low, the possibility of heparin induced coagulopathy should be 
entertained in cardiac patients that received reinfusate from the Sorin Xtra® ATS with 
ongoing postoperative bleeding in our institution.  A practical suggestion in these 
cases would be to quantify heparin activity either with a point of care device 
(TEG/ROTEM) or direct measurement of heparin concentration using an Anti-Xa 
assay and titrating heparin reversal accordingly. !  
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Tables 
Table 1: Available literature investigating heparin removal in autotransfusion systems. 
Author Year Autotransfusion device 
studied 
Residual heparin in washed blood 
(reported as mean ± standard 
deviation unless stated otherwise) 
Assay utilised 
 
Conclusion 
Umlas et al(33) 1981 Haemonetics Cell Saver In vitro study Grann assay (polybrene neutralization of heparin 
effect) 
Not stated 
Ottesen et al(59) 1982 Haemonetics Cell Saver 0.019 ± 0.02 IU/ml  Thrombin-protamine-heparin neutralization assay “of no significance” 
Paravicini et al(42) 1983 Haemonetics Cell Saver Maximum heparin level in one unit of 
cell-saver blood was 60 IU 
“a highly sensitive heparin test” “totally free of heparin” 
Sandmann et al(41) 1985 Haemonetics Cell saver 3 
Rapid Autotransfusion 
Machine 
0.16 IU/ml (IQR 0.0 – 0.46 IU/ml) Not stated Not stated 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
! 26!
Mc Shane et al(58) 1987 Dideco Autotrans BT 795 0.64± 0.3  IU/ml  
 
Not stated “..modification of the centrifugation and 
washing is required to lessen the high white 
cell count and heparin concentrations found in 
the saved blood.” 
Kling et al(40) 1988 Haemonetics Cell Saver 4  0.41 (IQR 0.07-0.77) IU/ml Anti-Xa chromogenic assay (antithrombin III added to 
samples but addition of pooled plasma not stated) 
[Testkombination Heparin, Boehringer Mannheim, 
Germany] 
“amount of heparin is not enough to provoke 
bleeding” 
Sistino et al(39) 1992 Haemonetics Cell Saver 4 0.0027 ± 0.03 IU/ml Anti-Xa chromogenic assay 
(Modification by addition of pooled plasma not 
stated) 
(Stachrom, Medtronic Hemotec, Inc., Englewood, 
CO, USA) 
“no clinical significance” 
Gravlee et al(60) 1992 Haemonetics cell saver <0.04 IU/ml with 750ml saline wash 
0.08-0.22 IU/ml with 500ml saline 
wash 
Whole blood heparin concentration (Hepcon, 
HemoTec Inc., Englewood, CO) 
“usual complete wash cycle do not contain 
clinically significant amounts of heparin” 
Rougé et al(38) 1993 Haemonetics Cell Saver 4 
Dideco/Shiley STAT 
BRAT 250 
0.269 ± 0.01 IU/ml 
0.223 ± 0.05 IU/ml 
0.463 ± 0.01 IU/ml 
Anti-Xa chromogenic assay (Modification by addition 
of pooled plasma not stated) 
(Stachrom Heparin, Diagnostica Stago, Asnieres, 
France) 
“virtual elimination of heparin” 
Kalra et al(37) 1993 Haemocell System 350 4.93 ± 0.91 IU/ml  
0.10 IU/ml mean plasma heparin level 
4 hours postoperative 
Anti-Xa chromogenic assay  
(Modification by addition of pooled plasma not 
stated) 
(Coatest Heparin kit, KabiVitrum B.V.Diagnostica, 
Amsterdam, The Netherlands) 
“plasma heparin concentration was negligible” 
Vorweg et al(36) 1998 Cell Saver 5 Measured range 0.00 – 2.44 IU/ml  [“Heparin Test für ACS (Fa. Date-Behring)”] “no irregular heparin load but,  if the volume 
of rinsing liquid is decreased or the pumpflow 
is increased, the heparin load is increased 
enormously” 
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Geiger et al(43) 1998 Dideco Compact A  
Haemonetics Haemolite 3 
Haemonetics Cell Saver 5 
Fresenius C.A.T.S. 
Medtronic AutoLog  
Medtronic Sequestra  
Transf. Tech OrtoPAT  
0.40 IU/ml  
0.29 IU/ml  
0.72 IU/ml  
1.17 IU/ml  
0.79 IU/ml  
0.67 IU/ml  
0.10 IUml  
(all values are median values) 
Not stated “very effective washout” 
Levy et al(44) 2001 Dideco Electa 5.0  <0.1 IU/ml 
Heparin elimination rate 98.7 ± 0.2%  
Not stated “Efficiently removes heparin” 
Cuby et al(45) 2001 Dideco Electa 5.0  <0.1 IU/ml  
Heparin elimination rate 98.7 ± 1.7%  
Not stated ‘Residual heparin levels low” 
Burman et al(11) 2002 Cobe BRAT 2 
Fresenius C.A.T.S. 
Medtronic Sequestra 
Haemonetics Cell Saver 5 
Dideco Compact A 
0.3 (measured range: 0 – 4.0) IU/ml Anti-Xa chromogenic assay  (Modification by 
addition of pooled plasma not stated) 
(Stachrom, Diagnostica Stago, Dundee, Scotland) 
“Heparin was effectively removed” 
Serrick et al(35) 2003 Cobe BRAT 2 
Medtronic Sequestra 1000 
Haemonetics Cell Saver 5 
Medtronic Autolog 
Fresenius C.A.T.S.  
0.80 ± 0.65 IU/ml  
0.61 ± 0.36 IU/ml 
0.19 ± 0.17 IU/ml 
0.39 ± 0.33 IU/ml 
0.73  ± 0.86 IU/ml 
Anti-Xa chromogenic assay 
(Modification by addition of pooled plasma not 
stated) 
“All devices adequately removed heparin” 
Kelleher et al(46) 2011 Cobe BRAT 2  
Haemonetics Cell Saver 5  
BRAT 2 
2001: 0.2 (0.0-0.4[0-1.9]) 
2002: 0.2 (0.1-0.5[0-1.7]) 
2003: 0.4 (0.2-2.3[0-1.7]) 
2004: 0.3 (0.2-0.5[0-0.8]) 
2005: 0.2 (0-0.4[0-1.7]) 
2006:0.3 (0-0.5[0-0.6]) 
Cell Saver 5 
2006: 0.4 (0.2-0.7[0-2.5]) 
2007: 0 (0.0-0.2[0-0.4]) 
year: median (IQR[range]) 
Anti-Xa chromogenic assay (Modification by addition 
of pooled plasma not stated)  
(Stachrom, Diagnostica Stago, Asnieres, France) 
“Consistent heparin removal” 
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Overdevest et al(47) 2012 Sorin Xtra® Heparin elimination rate 98.8-99.9%  Anti-Xa chromogenic assay (Modification by addition 
of pooled plasma not stated) 
(Roche Stago) 
removal rate, depending on wash set and wash 
speed “performs adequately” 
Notes: Year denotes the year the article was published. Note that Levy et al and Cuby et al’s articles were only published as abstracts.  
BRAT 2 and BRAT 250 (Cobe Cardiovascular, Quedgeley, UK); C.A.T.S. (Fresenius Kabi Ltd., Runcom, UK); Sequestra, Sequestra 1000, and AutoLog (Medtronic Ltd., Watford, UK); Cell Saver, Cell 
Saver 4, and Cell Saver 5 (Haemonetics, Braintree, MA, USA); Compact A, and Shiley STAT (Dideco, Sorin Biomedica UK, Quedgeley, UK); System 350 (Haemocell, Abington, UK); OrtoPAT (Transf. 
Tech, (Haemonetics), Braintree, MA, USA), Electa 5,0 (Dideco, Modena, Italy); Sorin Xtra® (Sorin Group, Mirandola, Italy);  Autotrans BT 795 (Dideco S.p.A., Mirandola, Italy); Rapid Autotransfusion 
Machine (Baylor College of Medicine, Houston). Note that the Sorin Group has acquired the Cobe and Dideco companies. 
Abbreviations:  IQR: interquartile range. 
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Figures 
 
Figure 1: Individual points and notched box-and-whisker plot of absolute 
heparin concentrations measured in reinfusate from Sorin Xtra® ATS. Mean 
heparin concentration 0.52 IU/ml; IQR 0.16 to 0.74 IU/ml; 95% confidence 
interval 0.30 to 0.66 IU/ml  
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Appendices 
 
Appendix A: Excel spreadsheat with data 
 
Test%results:%Sorin%Xtra®%Heparin%in%Cell%Saver%Blood ! ! 
! ! ! ! ! 
% % % Specimen%Registered AF10A 
Labno Name Locn Date AF10A 
STY7066351 SAMPLE!E1 X5147 20/05/2015 0.4 
STY7067004 SAMPLE!E3 X5147 20/05/2015 0.32 
STY7067007 SAMPLE!E4 X5147 20/05/2015 0.22 
STY7067012 SAMPLE!E5 X5147 20/05/2015 0.78 
STY7067019 SAMPLE!E6 X5147 20/05/2015 0.14 
STY7067022 SAMPLE!E02 X5147 20/05/2015 0.72 
STY7067024 SAMPLE!E8 X5147 20/05/2015 0.84 
STY7067026 SAMPLE!E9 X5147 20/05/2015 0.68 
STY7067030 SAMPLE!E10 X5147 20/05/2015 0.56 
STY7067033 SAMPLE!E11 X5147 20/05/2015 2.26 
STY7067045 SAMPLE!E11 X5147 20/05/2015 2.26 
STY7067058 SAMPLE!E14 X5147 20/05/2015 0.28 
STY7067063 SAMPLE!E15 X5147 20/05/2015 0.74 
STY7067068 SAMPLE!E16 X5147 20/05/2015 0.82 
STY7067072 SAMPLE!E17 X5147 20/05/2015 0.58 
STY7067078 SAMPLE!E18 X5147 20/05/2015 0.74 
STY7067085 SAMPLE!E19 X5147 20/05/2015 0 
STY7067089 SAMPLE!E21 X5147 20/05/2015 0 
STY7067093 SAMPLE!E22 X5147 20/05/2015 0 
STY7067103 SAMPLE!F2 X5147 20/05/2015 0.6 
STY7067104 SAMPLE!F3 X5147 20/05/2015 0.34 
STY7067106 SAMPLE!F4 X5147 20/05/2015 0.64 
STY7067109 SAMPLE!F5 X5147 20/05/2015 0 
STY7067110 SAMPLE!F6 X5147 20/05/2015 0.46 
STY7067112 SAMPLE!F7 X5147 20/05/2015 0.34 
STY7067113 SAMPLE!F8 X5147 20/05/2015 0.52 
STY7067118 SAMPLE!F9 X5147 20/05/2015 0.02 
STY7067120 SAMPLE!F10 X5147 20/05/2015 0.64 
STY7067500 SAMPLE!F11 X5147 20/05/2015 0.88 
STY7067513 SAMPLE!F12 X5147 20/05/2015 0 
STY7067514 SAMPLE!F13 X5147 20/05/2015 1.12 
STY7067515 SAMPLE!F14 X5147 20/05/2015 0.12 
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Appendix B: HREC acceptance letter 
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Appendix C: Consent form and information leaflet (English) 
!
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
 
Title of the Research Project: Residual heparin concentration in cell saver blood 
from the Sorin Xtra® autotransfusion system. 
 
Principal Investigator: Dr Mathilde Buys, Department of Anaesthesiology and 
Critical Care, Tygerberg Academic Hospital. CONTACT NUMBER: 021 
9385142 or 0716059345 
 
Introduction to a research project: your rights and responsibilities: 
1.! You are being invited to take part in a research project.   
2.! Please take some time to read the information presented here, which will explain 
the details of this project.   
3.! Please ask the study doctor any questions about any part of this project that you do 
not fully understand. It is very important that you are fully satisfied that you 
clearly understand what this research entails and how you could be involved.   
4.! Also, note that your participation is entirely voluntary and you are free to decline 
to participate.   
5.! If you say no, this will not affect you negatively in any way whatsoever.  You are 
also free to withdraw from the study at any point, even if you do agree to take 
part. 
6.! Please note that the Ethical and scientific aspects of this study have been carefully 
looked at by the Ethics committee for your protection. This study has been 
approved by the Committee for Human Research at Stellenbosch University 
(The Ethics committee) and will be conducted according to the ethical guidelines 
and principles of the international Declaration of Helsinki, South African 
Guidelines for Good Clinical Practice and the Medical Research Council (MRC) 
Ethical Guidelines for Research. 
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What is this research study all about? 
1.! This study will be conducted in the heart theatres at Tygerberg Academic Hospital.  
2.! Approximately 29 patients will be studied. 
3.! A standard operation will be performed. 
4.! As part of the ordinary running of heart operations, any of your own blood that is 
lost into the heart-lung machine is to be returned to you using a special blood 
conservation device.  This is done to minimise the use of blood from the blood bank 
in order to limit the side effects associated with banked blood. 
5.! This device washes your own blood before it is given back to you.  
6.! The purpose of this project is to check the quality of the washed blood. 
Specifically, we are interested in determining the amount of heparin (blood thinner 
or anticoagulant) remaining in the blood. 
7.! The project involves taking a small sample (approximately a teaspoon) of your 
processed blood for testing before we give the blood back to you.   The quality of 
the blood will not be changed in any way. 
 
Why have you been invited to participate? 
This project involves 29 patients undergoing elective heart operations like yourself. 
 
What will your responsibilities be? 
You have no additional responsibilities. Your operation will be conducted as usual.  
 
Will you benefit from taking part in this research? 
1.! This project aims at testing the quality of the blood product that we return to 
patients.  
2.! There will be no immediate benefit during your operation.  
3.! Future patients will benefit from this research.  
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Are there any risks involved in your taking part in this research? 
There are no additional risks involved if you take part in this project. 
What will happen in the unlikely event of some form of injury occurring as a 
direct result of your taking part in this research study? 
1.! It is extremely unlikely that injury can occur as a direct result of your taking part 
in this research project.  
2.! In the extremely unlikely event of injury, the University has insurance to cover 
such eventualities.  Such cases will be evaluated according to Association of 
British Pharmaceutical Industry compensation guidelines. 
 
If you do not agree to take part, what alternatives do you have? 
Your operation will be conducted in exactly the same way whether you decide to 
participate in this project or not. 
 
Who will have access to your medical records? 
1.! The information collected will be treated as confidential and protected.   
2.! If it is used in a publication, your identity will remain anonymous.   
3.! Only the investigators involved in this project will have access to your 
information.  
 
Will you be paid to take part in this study and are there any costs involved? 
1.! No you will not be paid to take part in the study.  
2.! There will be no costs involved for you, if you do take part. 
 
Is there anything else that you should know or do? 
1.! You can contact Dr Mathilde Buys at telephone 0716059345 if you have any 
further queries or encounter any problems regarding the study. 
2.! You can contact the Committee for Human Research at 021-938 9207 if you have 
any concerns or complaints that have not been adequately addressed by your study 
doctor. 
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3.! You will receive a copy of this information and consent form for your own 
records. 
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Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in 
a research study entitled Residual heparin concentration in cell saver blood from 
the Sorin Xtra® autotransfusion system. 
 
I declare that: 
 
1.! I have read or had read to me this information and consent form. 
2.! It is written in a language with which I am fluent and comfortable. 
3.! I have had a chance to ask questions and all my questions have been 
adequately answered. 
4.! I understand that taking part in this study is voluntary and I have not been 
pressurised to take part. 
5.! I may choose to leave the study at any time and will not be penalised or 
prejudiced in any way. 
 
 
Signed at (place) Tygerberg Academic Hospital on (date) …………....……….. 
........ 
 
 
 
......................................................................   ...................................................................  
Signature of participant Signature of witness 
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Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
1.! I explained the information in this document to 
………………………………….. 
2.! I encouraged him/her to ask questions and took adequate time to answer them. 
3.! I am satisfied that he/she adequately understands all aspects of the research, as 
discussed above. 
4.! I did/did not use an interpreter.  (If an interpreter is used then the interpreter 
must sign the declaration below. 
 
 
Signed at (place) Tygerberg Academic Hospital on (date) 
…………....………........... 
 
 
 
......................................................................   ...................................................................  
Signature of investigator Signature of witness 
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Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
 
1.! I assisted the investigator (name) ………………………………………. to 
explain the information in this document to (name of participant) 
……………..…………………………….. using the language medium of 
Afrikaans/Xhosa. 
2.! We encouraged him/her to ask questions and took adequate time to answer 
them. 
3.! I conveyed a factually correct version of what was related to me. 
4.! I am satisfied that the participant fully understands the content of this 
informed consent document and has had all his/her question satisfactorily 
answered. 
 
 
Signed at (place) Tygerberg Academic Hospital on (date) 
…………....……………….. 
 
 
 
......................................................................   ...................................................................  
Signature of interpreter Signature of witness 
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Appendix D: Informed consent and information leaflet (Afrikaans) 
 
DEELNEMERINLIGTINGSBLAD EN -TOESTEMMINGSVORM 
 
Titel van die Navorsingsprojek: Oorblywende heparien in sel-besparings bloed 
met die gebruik van die Sorin Xtra® autotransfusie toestel. 
 
Hoofnavorser: Dr Mathilde Buys, Departement Anestesiologie en Kritieke Sorg, 
Tygerberg Akademiese Hospitaal. KONTAKNOMMER: 021 9385142 of 
0716059345 
 
Inleiding tot navorsingsprojek: u regte en verantwoordelikhede: 
1.! U word uitgenooi om deel te neem aan ‘n navorsingsprojek. 
2.! Lees asseblief hierdie inligtingsblad op u tyd deur aangesien die detail van die 
navorsingsprojek daarin verduidelik word.   
3.! Indien daar enige deel van die navorsingsprojek is wat u nie ten volle verstaan 
nie, is u welkom om die navorsingsdokter daaroor uit te vra.   
4.! Dit is baie belangrik dat u ten volle moet verstaan wat die navorsingsprojek 
behels en hoe u daarby betrokke kan wees.   
5.! U deelname is ook volkome vrywillig en dit staan u vry om deelname te 
weier.   
6.! U sal op geen wyse hoegenaamd negatief beïnvloed word indien u sou weier 
om deel te neem nie.  U mag ook te eniger tyd aan die navorsingsprojek 
onttrek, selfs al het u ingestem om deel te neem. Hierdie navorsingsprojek is 
deur die Komitee vir Mensnavorsing van die Universiteit Stellenbosch 
goedgekeur en sal uitgevoer word volgens die etiese riglyne en beginsels 
van die Internasionale Verklaring van Helsinki en die Etiese Riglyne vir 
Navorsing van die Mediese Navorsingsraad (MNR). 
 
Wat behels hierdie navorsingsprojek? 
1.! Hierdie projek word slegs by Tygerberg Akademiese Hospitaal in die 
hartteaters uitgevoer.  
2.! Nagenoeg 29 pasiënte sal gewerf word vir die projek. 
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3.! ‘n Standaard operasie sal uitgevoer word. 
4.! In die uitvoering van ‘n hartoperasie word enige van u eie bloed wat verlore 
gaan in die hartlongmasjien aan u terugbesorg deur middel van ‘n spesiale 
bloedbesparingstoestel. Dit word gedoen om die gebruik van bloed vanaf die 
bloedbank te verminder en sodoende die newe-effekte geassosieer met die 
toediening van bloed vanuit die bloedbank te beperk. 
5.! Die toestel was u eie bloed voor dit aan u terugbesorg word. 
6.! Die doel van hierdie projek is om die kwaliteit van die gewasde bloed na te 
gaan. Ons is veral geinteresseerd in die hoeveelheid heparien (bloedverdunner 
of anti-stolmiddel) wat oorbly in die bloed na die wasproses. 
7.! Die projek behels die neem van ‘n bietjie (omtrent ‘n teelepel) van u 
geprosesseerde bloed vir ontleding voordat die bloed weer aan u oorgetap 
word.  Die bloed sal op geen manier verander of geaffekteer word nie. 
 
Waarom is u genooi om deel te neem aan hierdie projek? 
Die projek betrek 29 pasiënte wat elektiewe hartoperasies ondergaan soos uself. 
 
Wat sal u verantwoordelikhede wees? 
U het geen addisionele verantwoordelikhede nie. U operasie word op dieselfde manier 
uitgevoer ongeag u deelname aan hierdie studie aldan nie.  
 
Sal u voordeel trek deur deel te neem aan hierdie navorsingsprojek? 
1.! Hierdie projek beoog om die kwaliteit van die genoemde bloedproduk na te 
gaan en te verseker.  
2.! Daar is geen onmiddelike voordeel tydens u operasie nie.  
3.! Toekomstige pasiënte sal baatvind by hierdie projek.   
 
Is daar enige risiko's verbonde aan u deelname aan hierdie navorsingsprojek? 
Daar is geen addisionele risiko’s verbonde aan u deelname aan hierdie projek nie. 
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Wat sal gebeur in die onwaarskynlike geval van ‘n besering wat mag voorkom as 
gevolg van u deelname aan hiedie navorsingsprojek? 
1.! Dit is hoogs onwaarskynlik dat enige besering mag voorkom as ‘n direkte 
gevolg van u deelname aan hierdie navorsingsprojek. 
2.! In die hoogs onwaarskynlike geval van besering, het die Universiteit 
assuransie om sulke gebeurlikhede te dek. Enige sulke gevalle sal ge-evalueer 
word volgens die Association of British Pharmaceutical Industry-
vergoedingsriglyne. 
 
Watter alternatiewe is daar indien u nie instem om deel te neem nie? 
U operasie word op dieselfde manier uitgevoer ongeag u deelname aan hierdie studie. 
 
Wie sal toegang hê tot u mediese rekords? 
1.! Die inligting wat versamel word, word vertroulik en beskermd hanteer.  
2.! Die deelnemer sal anoniem bly indien dit gebruik sou word vir ’n publikasie.  
3.! Slegs die navorsers wat betrokke is by die studie sal toegang tot die inligting 
hê. 
 
Sal u betaal word vir deelname aan die navorsingsprojek en is daar enige koste 
verbonde aan deelname? 
1.! U word nie betaal vir deelname aan die navorsingsprojek nie.  
2.! Deelname aan die navorsingsprojek sal u niks kos nie. 
 
Is daar enigiets anders wat u moet weet of doen? 
 
1.! U kan Dr Mathilde Buys kontak by tel 0716059345 indien u enige verdere 
vrae het of enige probleme ondervind. 
2.! U kan die Komitee vir Mensnavorsing kontak by 021-938 9207 indien u enige 
bekommernis of klagte het wat nie bevredigend deur u studiedokter hanteer is 
nie. 
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3.! U sal ’n afskrif van hierdie inligtings- en toestemmingsvorm ontvang vir u eie 
rekords. 
 
 
 
 
 
 
Verklaring deur deelnemer 
 
Met die ondertekening van hierdie dokument onderneem ek, 
…….....................……….....……...……….., om deel te neem aan ’n 
navorsingsprojek getiteld:  Oorblywende heparien in sel-besparings bloed met die 
gebruik van die Dideco Electa Cell Separator toestel. 
 
Ek verklaar dat: 
 
1.! Ek hierdie inligtings- en toestemmingsvorm gelees het of aan my laat 
voorlees het en dat dit in ’n taal geskryf is waarin ek vaardig en gemaklik 
mee is. 
2.! Ek geleentheid gehad het om vrae te stel en dat al my vrae bevredigend 
beantwoord is. 
3.! Ek verstaan dat deelname aan hierdie navorsingsprojek vrywillig is en dat 
daar geen druk op my geplaas is om deel te neem nie. 
4.! Ek te eniger tyd aan die navorsingsprojek mag onttrek en dat ek nie op 
enige wyse daardeur benadeel sal word nie. 
 
Geteken te (plek) Tygerberg Akademiese Hospitaal op (datum) 
…………....………..  
 
 
......................................................................   ...................................................................  
Handtekening van deelnemer Handtekening van getuie 
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Verklaring deur navorser 
 
Ek (naam) …………………………………...……………… verklaar dat: 
 
1.! Ek die inligting in hierdie dokument verduidelik het aan 
…………………….............................................……….. 
2.! Ek hom/haar aangemoedig het om vrae te vra en voldoende tyd gebruik 
het om dit te beantwoord. 
3.! Ek tevrede is dat hy/sy al die aspekte van die navorsingsprojek soos 
hierbo bespreek, voldoende verstaan. 
4.! Ek ’n tolk gebruik het/nie ’n tolk gebruik het nie.  (Indien ’n tolk gebruik 
is, moet die tolk die onderstaande verklaring teken.) 
 
 
Geteken te (plek) Tygerberg Akademiese Hospitaal op (datum) 
…………....………... 
 
 
......................................................................   ...................................................................  
Handtekening van navorser Handtekening van getuie 
 
 !!!
Verklaring deur tolk 
 
Ek (naam) …………………………………...……………… verklaar dat: 
 
1.! Ek die navorser (naam) ……….............................…………………. 
bygestaan het om die inligting in hierdie dokument in Afrikaans/Xhosa 
aan (naam van deelnemer) ……………………………......................... te 
verduidelik. 
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2.! Ons hom/haar aangemoedig het om vrae te vra en voldoende tyd gebruik 
het om dit te beantwoord. 
3.! Ek ’n feitelik korrekte weergawe oorgedra het van wat aan my vertel is. 
4.! Ek tevrede is dat die deelnemer die inhoud van hierdie dokument ten volle 
verstaan en dat al sy/haar vrae bevredigend beantwoord is. 
 
 
Geteken te (plek) Tygerberg Akademiese Hospitaal op (datum) 
…………....………..  
 
 
......................................................................   ...................................................................  
Handtekening van tolk Handtekening van getuie 
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Appendix D: Data capture sheet (example) 
Bl!
!
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Heparin in Cell Saver Blood: Theatre Report Form 
Demographic Information/ Hospital label 
Patient identifier: Group:  Electa / Xtra 
Date:        /        / Weight:                 kg 
Age: Height:                 cm 
Gender: Procedure: 
Cell Saver Use (info on cell saver screen) 
Processed volume  
Collected volume  
Bowls  
Reservoir volume  
Time   
Hematocrit  
Heparin information  
Patient: Total heparin administered by anaesthesiologist  
Technologist: Total heparin administered - pump technologist (excluding cell saver)  
Cell saver: Total volume of heparin wash bag administered   
Transducer flush: Bag one: 200 ml with 500 IU heparin: total volume:   ¼   /    ½   /   ¾   /    all 
Transducer flush: Bag two: 200 ml with 500 IU heparin: total volume:   ¼   /    ½   /   ¾   /   all 
Volume of pericardial and pleural blood loss in the first 12 hours post-op  
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